

DOCTORAL THESIS

Characterization of furanodienone as a potential agent to treat breast cancer

Li, Yingwei

Date of Award:
2011

[Link to publication](#)

General rights

Copyright and intellectual property rights for the publications made accessible in HKBU Scholars are retained by the authors and/or other copyright owners. In addition to the restrictions prescribed by the Copyright Ordinance of Hong Kong, all users and readers must also observe the following terms of use:

- Users may download and print one copy of any publication from HKBU Scholars for the purpose of private study or research
- Users cannot further distribute the material or use it for any profit-making activity or commercial gain
- To share publications in HKBU Scholars with others, users are welcome to freely distribute the permanent URL assigned to the publication

**Characterization of Furanodienone as a Potential Agent to Treat
Breast Cancer**

LI Yingwei

**A thesis submitted in partial fulfillment of the requirements
for the degree of
Doctor of Philosophy**

Principal Supervisor: Prof. FONG Wang Fun, David.

Hong Kong Baptist University

June 2011

ABSTRACT

Breast cancer is the most common cancer and the second leading cause of women death worldwide. Several receptors including ER α , EGFR and HER2 play an important role in the development and progression of breast cancer. To date, endocrine therapy blocking estrogen receptor alpha (ER α) activity and HER2 targeted therapies have been shown to be promising approaches in the treatment of breast cancer. However, not all patients respond to these agents and identification of novel agents that can inhibit ER α , EGFR and HER2 signaling remains important. The aims of this study were to investigate furanodienone, an active chemical component isolated from *Rhizoma Curcumae* whether had anti-cancer activities and inhibited ER α , EGFR/HER2 signaling in human breast cancer cells.

In HER2-overexpressing human breast cancer cells, we observed that furanodienone caused cell cycle arrest in BT474 cells and induced apoptosis in SKBR3 cells. Furanodienone interfered with EGFR/HER2 signaling in treated cells as shown by decreases in phosphorylated EGFR, HER2, Akt, Gsk3 β and an increase in p27^{kip1} protein. Furanodienone also inhibited EGF-induced phosphorylation of EGFR, HER2, Akt and Gsk3 β resulted in inhibiting EGF-induced cell cycle progression in BT474 cells and EGF-induced cell growth in both BT474 and SKBR3 cells. In BT474 and SKBR3 cells, EGFR-specific siRNA knockdown did not affect the cell growth inhibitory effect of furanodienone. On the contrary, specific siRNA knockdown of HER2 increased cellular resistance to furanodienone toxicity. In HER-2 deficient MDA-MB-231 cells the transfection and expression of HER2 increased the sensitivity of cells to furanodienone toxicity.

In ER α -positive MCF-7 and T47D cells, furanodienone inhibited cell proliferation in a dose (10–160 μ M) dependent manner. ER α -negative MDA-MB-231 cells were less sensitive to furanodienone than MCF-7 and T47D cells. Furanodienone could effectively block 17 β -estradiol (E2)-stimulated MCF-7 cell proliferation, cell cycle progression and induce apoptosis evidenced by the flow cytometric detection of sub-G1 DNA content and the appearance of apoptotic nuclei after DAPI staining. Furanodienone specifically down regulated ER α protein and mRNA expression levels without altering ER β expression. Furanodienone treatment inhibited E2-stimulation of estrogen response element (ERE)-driven reporter plasmid activity and ablated E2-targeted gene (e.g. c-Myc, Bcl-2 and cyclin D1) expression which resulted in the inhibition of cell cycle progression and cell proliferation, and in the induction of apoptosis. Knockdown of ER α in MCF-7 cells by ER α -specific siRNA decreased the cell growth inhibitory effect of furanodienone.

In conclusion, furanodienone were able to inhibit EGFR/HER2 signaling pathway in HER2-overexpressing BT474 and SKBR3 cells. More importantly the effect of furanodienone was specifically dependent on HER2, but not EGFR, expression. Furanodienone also inhibited ER α signaling in ER α -positive MCF-7 cells. These results

suggest that furanodienone and its related compounds may provide novel approaches for the prevention and treatment of breast cancers.

TABLE OF CONTENTS

DECLARATION.....	i
ABSTRACT.....	ii
ACKNOWLEDGEMENT.....	iv
TABLE OF CONTENTS.....	v
LIST OF TABLES.....	ix
LIST OF FIGURES.....	x
LIST OF ABBREVIATIONS.....	xii
CHAPTER 1 GENERAL INTRODUCTION.....	1
CHAPTER 2 LITERATURE REVIEW.....	7
2.1 Breast cancer epidemiology.....	7
2.2 Risk factors of breast cancer.....	7
2.3 Symptoms and types of breast cancer.....	9
2.3.1 Symptoms.....	9
2.3.2 Breast cancer classifications.....	9
2.3.2.1 Stage.....	10
2.3.2.2 Histopathology.....	10
2.3.2.3 Receptor status.....	10
2.4 Breast cancer therapy.....	11
2.4.1 Surgery.....	11
2.4.2 Radiation Therapy.....	11
2.4.3 Chemotherapy.....	12
2.4.4 Targeted therapy.....	12
2.4.5 Hormonal Therapy.....	12
2.5 Estrogen receptor alpha (ER α) signaling pathway and breast cancer.....	13
2.5.1 The Biology of Estrogen Receptor.....	13
2.5.2 Estrogen receptor signaling pathway.....	14
2.5.3 Genes involved in estrogen action in breast cancer.....	16
2.5.3.1 c-Myc.....	16
2.5.3.2 Cyclin D1.....	17
2.5.3.3 Bcl-2.....	17
2.5.4 Estrogen and breast cancer.....	19

2.6 ErbB signaling and breast cancer.....	20
2.6.1 ErbB family structure.....	20
2.6.2 HER ligands.....	21
2.6.3 Receptor activation.....	22
2.6.4 Activation of PI3K/Akt signaling pathway.....	23
2.6.5 Activation of the MAPK kinase cascade.....	27
2.6.6 ErbB signaling and cell cycle.....	28
2.6.7 ErbB family and cancer.....	30
2.6.8 Targeting ErbB signaling network in breast cancer.....	32
2.6.8.1 EGFR/HER2 targeted therapies.....	33
2.6.8.2 VEGF targeted therapies.....	33
2.6.8.3 Targeted RAS/ERK pathway.....	34
2.6.8.4 Targeted PI3K/Akt pathway.....	35
2.6.8.5 Heat-shock protein 90 (Hsp90) inhibitors.....	37
2.7 Trastuzumab in breast cancer therapy.....	38
2.7.1 Mechanisms of action of trastuzumab.....	38
2.7.2 Mechanism of trastuzumab resistance.....	40
2.7.2.1 Altered receptor-antibody binding.....	40
2.7.2.2 Alternative signaling.....	41
2.7.2.3 Aberrant activation of downstream signaling.....	41
2.7.2.4 PIK3CA-activating mutation.....	42
2.7.2.5 Downregulation of p27.....	42
2.7.3 Potential therapeutic strategies for overcoming trastuzumab resistance.....	43
2.8 Natural compounds targeted ErbB signaling.....	45
2.9 Rhizoma Curcumae.....	46
CHAPTER 3 MATERIALS AND METHODS.....	52
3.1 Reagents and antibodies.....	52
3.2 Isolation of furanodienone.....	53
3.3 Cell culture and furanodienone treatment.....	54
3.4 Cell growth assay.....	55
3.5 Flow cytometric analysis of cellular DNA content.....	56
3.6 Evaluation of apoptosis.....	57
3.7 Western blot analysis.....	58
3.8 Reverse transcription–PCR.....	59

3.9 Estrogen response element-luciferase assay.....	60
3.10 Transient transfection of siRNA.....	61
3.11 Plasmid construction and transfection.....	61
3.12 HER Kinase Assay.....	62
3.13 Statistical analysis.....	63
CHAPTER 4 FURANODIENONE INDUCES CELL CYCLE ARREST AND APOPTOSIS BY SUPPRESSING EGFR/HER2 SIGNALING IN HER2-OVEREXPRESSING HUMAN BREAST CANCER CELLS.....	64
4.1 Abstract.....	64
4.2 Introduction.....	65
4.3 Experimental design.....	68
4.4 Results.....	69
4.4.1 Identification of furanodienone.....	69
4.4.2 Furanodienone inhibited cell proliferation in HER2-overexpressing human breast cancer cells.....	69
4.4.3 Furanodienone treatment induced G1 arrest in BT-474 cells.....	70
4.4.4 Furanodienone treatment induced apoptosis in SKBR3 cells.....	70
4.4.5 Furanodienone inhibited EGF-stimulated cell cycle progression and cell proliferation in BT-474 and SKBR3 cells.....	70
4.4.6 Furanodienone inhibited EGFR/HER2 signaling in BT474 and SKBR3 cells	71
4.4.7 Furanodienone blocked EGF-activated EGFR/HER2 downstream signaling..	71
4.4.8 Anti-proliferation effects of furanodienone on BT474 and SKBR3 cells were independent from EGFR expression level.....	72
4.4.9 HER2 may have a role in the anti-proliferation action of furanodienone on BT474 and SKBR3 cells.....	72
4.5 Discussion.....	73
4.6 Illustrations.....	76
CHAPTER 5 FURANODIENONE INHIBITS CELL PROLIFERATION AND SURVIVAL BY SUPPRESSING ERα SIGNALING IN HUMAN BREAST	

CANCER MCF-7 CELLS.....	96
5.1 Abstract.....	96
5.2 Introduction.....	97
5.3 Experimental design.....	99
5.4 Results.....	100
5.4.1 Furanodienone inhibited the proliferation of MCF-7, T47D and MDA-MB-231 cells.....	100
5.4.2 Furanodienone selectively down-regulated the expression level of the ER α receptor subtype in MCF-7 cells.....	100
5.4.3 Furanodienone treatment inhibited E2-induced proliferation of MCF-7 cells.....	101
5.4.4 Furanodienone treatment disrupted E2-induced cell cycle progression in MCF-7 cells.....	101
5.4.5 Apoptotic morphological features were observed in furanodienone treated MCF-7 cells.....	102
5.4.6 Furanodienone treatment disrupted E2-stimulated estrogen response element promoter activity.....	102
5.4.7 Furanodienone suppressed ER α -targeted gene expression in MCF-7 cells...	102
5.4.8 Anti-proliferation effect of Furanodienone on MCF-7 cells was dependent on ER α expression.....	103
5.4.9 Furanodienone treatment disrupted E2-induced cell cycle progression in T47D cells.....	103
5.4.10 Furanodienone induced cell death in MDA-MB-231 cells.....	104
5.5 Discussion.....	104
5.6 Illustrations.....	107
CHAPTER 6 GENERAL DISCUSSION AND CONCLUSION.....	122
REFERENCES.....	126
PUBLICATIONS.....	159
CURRICULUM VITAE.....	160